Investor Update

Basel, 6 June 2008

Roche Investor Science Event: EULAR 2008

Invitation to Roche’s analyst briefing on Actemra and MabThera

Friday, June 13th 2008 in Paris

We are pleased to invite you to our Analyst briefing to discuss the data on Actemra and MabThera presented during the 2008 EULAR Conference (European League Against Rheumatism) in Paris from June 11th – 14th, 2008. In addition, Roche will provide an update on its pipeline in RA and autoimmune diseases.

Venue: Hotel Concorde la Fayette
3, Place du Général Koenig
75017 Paris, France
Tel.: +33 1 4068 5068
Fax: +33 1 4068 5043
http://www.concorde-lafayette.com/en/

Date: Friday, 13th June, 2008
Meeting room “Sisley 1 and 2”
PLEASE NOTE NEW START TIME
Time:  12.30 pm to 02.00 pm CEST (Paris)
11.30 am to 01.00 pm GMT (UK)
06.30 am to 08.00 am EDT (USA)

Reception: Buffet lunch will be available from 12.00 pm.

Speakers:

Prof. Paul Emery, arc Professor of Rheumatology, Head of Academic Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and Clinical Director (Rheumatology), Leeds Teaching Hospitals Trust, Leeds, UK

Dr. Urs Schleuniger, Vice President Strategic Marketing Inflammation and Head of Inflammation Disease Biology Leadership Team, Roche Palo Alto

Dr. Jonathan Leff, Vice President, Head of Inflammation Clinical Development, Roche Palo Alto

Dr. Karl Mahler, Head of Investor Relations, Roche Basel

Telephone Conference

Analysts are invited to dial in to the conference call using the following dial-in numbers:

+41 (0) 91 610 56 00 (Europe)

+1 (1) 866 291 4166 (USA)  

+44 (0) 207 107 0611 (UK)  

Please dial in to the conference call 10 – 15 minutes before the call is scheduled to start.

Webcast

Alternatively, a live audio webcast can be accessed via http://ir.roche.com (listen only, no access to speakers).

Presentation slides will be posted prior to the event on the Roche IR website http://ir.roche.com.